Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times

Looking Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 13.56% since its last report. The company recently reported that it has 5.36 million shares sold short, which is 0.67% of all regular shares that are available for trading.

Benzinga

Check Out What Whales Are Doing With LLY

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease

Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

Benzinga

Here's How Much $100 Invested In Eli Lilly 5 Years Ago Would Be Worth Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 13.68% on an annualized basis.

Benzinga

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

Benzinga

Eli Lilly And 3 Other Stocks Sold By Insiders

Although US crude oil futures traded higher this morning, there were a few notable insider trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…

Benzinga

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab

Benzinga

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

Benzinga

US FDA Advisers Say More Data Needed for Cancer Drug Tested in China

A panel of outside advisers to the US Food and Drug Administration on Thursday voted to recommend that Innovent Biologics Inc and Eli Lilly and Co be required to conduct a trial of their lung cancer drug that is applicable to the US population. Data submitted to the FDA for…

Asharq Al-Awsat

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly And Co (NYSE: LLY) has

Benzinga

Eli Lilly: Q4 Earnings Insights

Eli Lilly (NYSE:LLY) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:25 AM. Here's what investors need to know about the announcement.

Benzinga

A Preview Of Eli Lilly's Earnings

Eli Lilly (NYSE:LLY) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Eli Lilly will likely report an Earnings Per Share (EPS) of $2.19.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

Benzinga's options scanner just detected over 12 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $597,272. At the same time, our algo caught 7 for a total amount of 518,954.

Benzinga

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to

Tribune News Service

Michigan AG to investigate Eli Lilly insulin prices, but state courts could prove an obstacle

Michigan Attorney General Dana Nessel plans to investigate Eli Lilly's insulin pricing but will have to first overturn Michigan court precedent in order to push forward with the probe.

Benzinga

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 13 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

The Independent UK

FDA halts use of antibody drugs that don't work vs. omicron

U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant

Benzinga

If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 12.31% on an annualized basis.

Benzinga

Expert Ratings For Eli Lilly

Over the past 3 months, 7 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Looking Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 4.0% since last its last report. The company recently reported that it has 6.19 million shares sold short, which is 0.78% of all regular shares that are available for trading.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.

Kiplinger

The Best Health Care ETFs to Buy

The best health care ETFs offer diversification across medical industries as well as exposure to a sector with lower volatility than the broader market.

1 … 26 27 28 29

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

US Food and Drug Administration

62 stories

Eli Lilly and Company

60 stories

Eli Lilly And Co

55 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.